A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2022

Conditions

Migraine

Interventions

DRUG

Lu AG09222

Lu AG09222 will be administered per schedule specified in the arm description.

DRUG

Placebo

Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.

Trial Locations (1)

PAREXEL International, Glendale

All Listed Sponsors

lead

H. Lundbeck A/S

INDUSTRY